Core Viewpoint - The stock of Beijing Zhaoyan New Drug Research Center Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days in July 2025 [2][3]. Group 1: Stock Trading Abnormality - The company's stock price increased significantly on July 25, 28, and 29, 2025, with a cumulative closing price deviation exceeding 20%, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][3]. Group 2: Company Operations and Major Events - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external business environment that would affect the stock price [4]. - A self-examination and inquiry with the controlling shareholder and actual controller revealed no undisclosed major events that could impact the stock price, including significant asset restructuring or share issuance [5]. - The company did not identify any media reports or market rumors that require clarification or response, nor any other significant events that could substantially affect the stock price [6]. Group 3: Insider Trading and Board Statement - The company verified that there were no transactions involving the company's stock by the controlling shareholder, actual controller, directors, supervisors, or senior management during the period of abnormal trading fluctuation [7]. - The board of directors confirmed that there are no undisclosed matters or plans that should have been disclosed according to the relevant regulations, and previous disclosures do not require correction or supplementation [9].